Medpace (MEDP) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MEDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEDP, but not buy additional shares or sell existing shares.
View MEDP analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1 year price objectives for Medpace's stock. Their MEDP share price forecasts range from $250.00 to $273.00. On average, they anticipate the company's stock price to reach $264.33 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for MEDP or view top-rated stocks among Wall Street analysts.

Medpace's stock was trading at $212.41 at the start of the year. Since then, MEDP stock has increased by 14.6% and is now trading at $243.49.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 23rd 2023.
View our MEDP earnings forecast.

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Monday, July, 24th. The company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.90 by $0.03. The company had revenue of $460.90 million for the quarter, compared to analysts' expectations of $433.75 million. Medpace had a trailing twelve-month return on equity of 72.88% and a net margin of 16.06%. The firm's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS.

ETFs with the largest weight of Medpace (NASDAQ:MEDP) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), Argent Mid Cap ETF (AMID), First Trust Health Care AlphaDEX Fund (FXH), Invesco S&P MidCap Quality ETF (XMHQ), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

Medpace issued an update on its FY 2023 earnings guidance on Monday, July, 24th. The company provided EPS guidance of $8.04-$8.50 for the period, compared to the consensus estimate of $8.23. The company issued revenue guidance of $1.84 billion-$1.88 billion, compared to the consensus revenue estimate of $1.78 billion.

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.11%), Wasatch Advisors LP (5.13%), State Street Corp (2.20%), Riverbridge Partners LLC (2.14%), Boston Trust Walden Corp (1.80%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends.

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDP stock can currently be purchased for approximately $243.49.

Medpace (NASDAQ:MEDP) has a market capitalization of $7.44 billion and generates $1.46 billion in revenue each year. The company earns $245.37 million in net income (profit) each year or $8.37 on an earnings per share basis.

The company employs 5,200 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The official website for the company is www.medpace.com. The company can be reached via phone at (513) 579-9911, via email at investor@medpace.com, or via fax at 513-579-0444.